Prostate cancer is the most common cancer in men and the third most common cause of cancer death. Screening has been proposed as a means for reducing its burden. PSA-based screening was shown to reduce prostate cancer mortality, but it causes substantial overdiagnosis of indolent cases, and therefore it has not been widely introduced. The rationale of our trial is to reduce overdiagnosis but retain or increase the mortality impact by using two blood-based tests (PSA and a kallikrein panel) and magnetic resonance imaging. Our preliminary results indicate increased detection of clinically significant cancer, but a very limited number of low-risk cases. The next stage includes evaluation of intermediate indicators of screening effectiveness, optimising the screening algorithm and development of novel methods for predicting risk of clinically significant prostate cancer and prognostic indicators using the biological samples and digital data collected in the trial.

2024

2028